Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy.

The findings indicate a significant association between plasma acylcarnitines with prognosis and treatment responses in patients with IgAN, which suggest its role as a potential penal of biomarker for IgAN.